A Phase I trial of neuroprotective therapies for the treatment of neurological conditions caused by chemotherapy
Latest Information Update: 17 Nov 2022
Price :
$35 *
At a glance
- Drugs Neuroprotectants (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions
- 12 Sep 2018 New trial record
- 27 Aug 2018 According to a Magnolia Neurosciences Corporation media release, the company expects to initiate this trial in the second half of 2019.